AbCellera Biologics (NASDAQ:ABCL) Announces Quarterly Earnings Results

AbCellera Biologics (NASDAQ:ABCL) released its quarterly earnings results on Monday. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.08, FiscalAI reports. The business had revenue of $8.32 million during the quarter, compared to analysts’ expectations of $5.41 million. AbCellera Biologics had a negative net margin of 181.75% and a negative return on equity of 14.70%. During the same quarter in the previous year, the company earned ($0.15) EPS.

Here are the key takeaways from AbCellera Biologics’ conference call:

• Interim Phase I data for ABCL635 showed generally well?tolerated safety with no liver?related adverse events, linear PK supporting monthly dosing, and sustained dose?dependent suppression of testosterone, FSH and LH consistent with strong NK3R target engagement.
• The randomized Phase II (?80 patients, single 600 mg SC dose) is enrolling and remains on track for a top?line efficacy/safety readout in Q3 2026; management says a positive result would be highly de?risking and support late?stage development and expansion into cancer?related VMS indications.
• Pipeline progress includes an expected Phase I top?line for ABCL575 in Q4 2026, two IND?enabling programs (ABCL688, ABCL386) targeted to reach the clinic by end?2027, and a planned fifth development candidate selection in H1 2026, though program details remain limited.
• AbCellera ended Q1 with ~CAD 531M cash and marketable securities plus ~CAD 125M committed government funding (?CAD 655M available liquidity), which management says funds at least three years of pipeline investment despite a Q1 net loss of ~CAD 43M and lower research?fee revenue as the company shifts to internal programs.

AbCellera Biologics Price Performance

NASDAQ ABCL traded down $0.09 during trading on Wednesday, hitting $4.87. 1,539,060 shares of the company’s stock traded hands, compared to its average volume of 4,897,826. The stock has a fifty day moving average of $3.80 and a two-hundred day moving average of $3.83. AbCellera Biologics has a 12-month low of $1.94 and a 12-month high of $6.51. The firm has a market cap of $1.49 billion, a P/E ratio of -10.14 and a beta of 1.02.

Institutional Investors Weigh In On AbCellera Biologics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Invesco Ltd. grew its position in AbCellera Biologics by 114.6% during the 1st quarter. Invesco Ltd. now owns 24,146 shares of the company’s stock worth $54,000 after acquiring an additional 12,893 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of AbCellera Biologics by 3.5% during the second quarter. Geode Capital Management LLC now owns 363,188 shares of the company’s stock valued at $1,246,000 after purchasing an additional 12,301 shares during the period. Creative Planning grew its holdings in shares of AbCellera Biologics by 6.9% in the second quarter. Creative Planning now owns 41,003 shares of the company’s stock worth $141,000 after purchasing an additional 2,656 shares during the last quarter. Raymond James Financial Inc. increased its stake in shares of AbCellera Biologics by 17.0% in the second quarter. Raymond James Financial Inc. now owns 28,049 shares of the company’s stock worth $96,000 after buying an additional 4,070 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of AbCellera Biologics by 1,304.5% in the second quarter. Bank of America Corp DE now owns 224,365 shares of the company’s stock worth $770,000 after buying an additional 208,390 shares during the period. Institutional investors own 61.42% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of AbCellera Biologics from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Cantor Fitzgerald assumed coverage on AbCellera Biologics in a report on Tuesday, May 5th. They issued an “overweight” rating and a $7.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of AbCellera Biologics in a research report on Monday, April 20th. Finally, JonesTrading initiated coverage on AbCellera Biologics in a research report on Friday, April 10th. They issued a “buy” rating and a $11.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, AbCellera Biologics has a consensus rating of “Moderate Buy” and a consensus price target of $8.17.

About AbCellera Biologics

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.